Successful Collaboration and Workshop: NGS in the Modern Clinical Lab
11/23/23
11/25/23
Offline
Athens, Greece
Share
In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.
Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.
Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.
In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.
Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.
Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.
In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.
Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.
Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.
In collaboration with our Greece partner Varelas S.A. Chemicals and Diagnostics, the Hellenic Microbiology Association, the University of Athens and the University of Thessaly, we co-organized the 'NGS in the Modern Clinical Lab: From Theory to Practical Applications' workshop in Athens from November 23-25, 2023.
Over three days, attendees participated in seminars and hands-on wet lab sessions, exploring the use of NGS and MGI DNBSEQ technology in the laboratory. We showcased the efficiency of MGI’s DNSEQ G99 and Platform of Microorganisms Fast Identification (PFI) pipeline in Metagenomics.
Thrilled about potential collaborations, we look forward to sharing MGI's groundbreaking innovations with the market. The workshop was a success, reinforcing our commitment to advancing genomics and sequencing technologies.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About VARELAS S.A.
Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals, VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.
About VARELAS S.A.
Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals, VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.
About VARELAS S.A.
Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals, VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.
About VARELAS S.A.
Founded in the early '50s as N.D. VARELAS S.A. Pharmaceuticals & Chemicals, VARELAS S.A. shifted its focus to the in vitro Diagnostics market in 1978. Renamed VARELAS S.A. Chemicals & Diagnostics in 1993, it later expanded into the Life Science Market in 1997. Today, VARELAS S.A. is a leading supplier to both Public and Private Diagnostic and Life-science Research Laboratories. Pioneering Total Quality Management, it obtained ISO 9002 certification in 2001, and its Quality Management System is presently ISO 9001:2008 and ISO 13485:2003 certified. With 25 highly skilled personnel, the company attributes its success to its commitment to quality. For more information, please visit the varelas.gr.
METAGENOMIC SEQUENCING
COLLABORATION
VARELAS S.A.
Share this article :
Share
Nov 4, 2024
Join us for the Future of Omics Conference in Stockholm
Do you want to learn about innovative solutions within Next Generation Sequencing? On November 4th we are organizing our first Future of Omics Nordic Station at Karolinska Institute in Stockholm. Experience a day with insights from leading experts in the field, engage in discussions and valuable networking.
Sep 10, 2024
MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference
Discover insights from the "Future of Omics" event, where leading experts discussed innovations in genomics, proteomics, and metabolomics. Explore key takeaways on advancing research and technology, shaping the future of personalized medicine and healthcare. Join us in celebrating the progress in omics!
Jun 1, 2024
MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).